PLAS-FIGHTER 

Exploiting plasmid-bacteria interactions to fight the evolution of antimicrobial resistance 

A comprehensive view of resistance

From source to treatment 

Through the PLASFIGHTER project, our team will drive significant advances in understanding and combating antimicrobial resistance (AMR). By dissecting plasmid-bacteria interactions at unprecedented resolution, we will answer longstanding questions regarding plasmid fitness costs, plasmid-bacteria associations and their role in generating superbugs. 

Targeting AMR at its source 
PLAS-FIGHTER explores a revolutionary strategy to combat antimicrobial resistance by targeting the very elements that confer resistance: plasmids. 

Protecting microbial balance 
Our approach affects only AMR subpopulations, avoiding disruptions to healthy gut bacteria and the increased risk of dysbiosis seen with traditional antimicrobials. 

Bridging science and medicine 
This research connects evolutionary biology and clinical microbiology, offering insights into bacterial-plasmid interactions and practical strategies to fight AMR. 

Unravelling AMR complexity 

Cutting-edge tools and models to decode resistance dynamics 

We apply CRISPRi screening to clinically relevant multidrug-resistant enterobacteria, allowing precise genetic manipulation. Moving beyond single cultures, we analyse microbial interactions within complex communities, including the human gut microbiota. Our interventions are tested in advanced models that mimic real-world environments where AMR evolves. By integrating genomic, transcriptomic, and phenotypic data, we create comprehensive models of plasmid-host interactions to drive innovative AMR solutions. 

Breaking new ground  

Potential applications of our results at PLAS-FIGHTER  

Novel therapeutics 
Development of compounds specifically targeting bacteria carrying AMR plasmids, providing alternatives to traditional antibiotics in clinical settings. 

Resistance prevention 
Strategies to limit the spread of resistance genes in healthcare environments and community settings through targeted interventions. 

Diagnostic tools  
New methods to rapidly identify plasmid-mediated resistance mechanisms, enabling more precise treatment selection in clinical practice. 

Microbiome protection   
Approaches that eliminate resistant bacteria whilst preserving beneficial microbiota, reducing collateral damage from antimicrobial treatments.